On Oct. 27, 2016, Roswell Park Cancer Institute announced it had received authorization from the U.S. Food and Drug Administration (FDA) to begin offering the lung cancer treatment vaccine CIMAvax-EGF to a limited number of patients through a clinical trial, making the center the first American institution to receive FDA permission to sponsor testing of a Cuban medical therapy in the U.S.

Roswell Park also received authorization from the U.S. Department of the Treasury to establish a joint business venture with the CIM, which will be the first U.S.-Cuban joint venture licensed to undertake research, development, manufacture and marketing of biotech products.